Sirion Biotech GmbH
New opportunities with advanced viral vector technologies for novel therapies & vaccines
SIRION Biotech CEO presents to Europe’s Investment Professionals in Frankfurt
Advanced viral vector technologies represent a new class of ‘compounds’ in modern drug & vaccine developments, similar to antibody technologies 20 years ago. Classically used to understand disease by genetic modelling, viral vectors have recently been entered in clinical studies as therapeutic elements that are now turning into approved therapies. Investment professionals see a multi-billion market potential for the coming years. Dr. Christian Thirion, CEO of Munich based SIRION Biotech, disclosed in Frankfurt that his company entered into 3 industrial deals in 2015, potentially worth EUR 50 M in milestone and license payments over the coming 10-15 years. First milestone payments are expected in 2016. The company specializes in innovative viral vector technologies to improve gene delivery and overcome technological bottlenecks that are holding back broad scale success of gene therapy. Outstandingly, SIRION masters all 3 vector platforms relevant for modern gene therapy; adenovirus, lentivirus and adeno-associated virus. This versatility supports a range of gene therapeutic frontiers from different research directions. A new topic of utmost relevance to oncology is CAR-T cell therapy, an intriguing technique which can be greatly improved with advanced viral vectors. Several big names in the industry are reporting progress in this field, amongst them companies such as Novartis, Bluebird, Cellectis, Kite and Juno, just to name a few. Dr. Thirion’s current development priorities center around novel AAV toolkits and directed evolution to modify AAV’s. AAVs are the most fitting viral vectors to be used systemically in patients, which explains why interest in these technologies is high and researched by companies such as Baxalta/Shire, Spark or UniQure. Viral vector based vaccines are another important field in which SIRION and the University of Copenhagen are entering preclinical studies to follow up on promising results, combining adenovirus with MVA vectors to boost immunization successes. About SIRION Biotech www.SIRION-Biotech.com SIRION Biotech started in Munich in 2007 with the idea of developing next generation viral vectors for gene therapy and vaccines and of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION’s technologies have been validated in over 500 single projects with more than 150 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies both for research and clinical studies. Contact SIRION Biotech: SIRION BIOTECH GmbH Dr. Christian Thirion Am Klopferspitz 19 D-82152 Martinsried Tel.: +49-89-700 961 99-15 eMail: Thirion@SIRION-Biotech.com www.SIRION-Biotech.com End of Media Release Issuer: Sirion Biotech GmbH Key word(s): Research/Technology
2016-06-16 Dissemination of a Press Release, transmitted by DGAP – a service of EQS Group AG. |
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden